Harpoon Therapeutics (ticker: HARP) is a clinical-stage immunotherapy company developing a novel class of T cell engagers that harness the power of the body’s immune system to treat patients suffering from cancer and other diseases. T cell engagers are engineered proteins that direct a patient’s own T cells to kill target cells that express specific proteins, or antigens, carried by the target cells. Using its proprietary Tri-specific T cell Activating Construct (TriTAC®) platform, Harpoon is developing a pipeline of novel TriTACs initially focused on the treatment of solid tumors and hematologic malignancies. HPN217 targets BCMA and is in a Phase 1/2 trial for relapsed, refractory multiple myeloma. HPN328 targets DLL3 and is in a Phase 1/2 trial for cancers expressing DLL3, initially focused on small cell lung cancer and other tumors with high-grade neuroendocrine features. Harpoon is led by an experienced management team. The company emphasizes a collegial, collaborative environment and has a strong record of scientific innovation, pioneering protein engineering, expertise in tumor immunology and pre-clinical and clinical research. For additional information about Harpoon Therapeutics, please visit www.harpoontx.com.
We are seeking a highly motivated individual to join the clinical team to oversee one or more early phase clinical trials and contribute to the successful development of Harpoon’s novel T cell engagers.
- This position reports to the CMO. Responsible for the design and execution of clinical trials, and for clinical documents to support INDs. Develop and maintain strong working relationships with external stakeholders including principal investigators and key opinion leaders. The Medical Director will work closely with the clinical operations, regulatory, biostatistics, and translational medicine functions and with CROs.
- Responsible for design and execution of clinical trial protocols.
- Be the Medical lead on drug development project teams.
- Medical input on pharmacovigilance activities.
- Work with project team leader and clinical sub-teams on formulating and executing clinical product strategy.
- Analyze clinical and safety data and present clinical results in presentation and report form.
- Contribute meaningfully to strategic discussions regarding drug development strategy with attention to relevant endpoints, regulatory paths and commercial landscape for multiple oncology indications.
- Represent the company to Key Opinion Leaders, Principal investigators, and Regulatory Agencies.
- May manage consultants initially. Manage others as the role / projects grow.
Skills and Qualifications
- MD required; oncology training preferred.
- Two or more years of experience in pharmaceutical clinical development Phase 1 – Phase 3; immuno-oncology preferred, or academic experience with clinical trials.
- Must be willing and able to be hands on: Go to clinical sites as needed with clinical operations / CROs. Interact with cross functional internal teams, KOLs, investigator personnel and others. Represent the company and present data at meetings.
- Excellent verbal and written communication, strong organizational and interpersonal skills.
- Ability to work both independently and collaboratively with cross-functional teams.
Harpoon anticipates that the annual base salary for this position could range from between $250,000.00 - $300,000.00 and will depend, in part, on the successful candidate’s credentials for the role, including education, qualifications, and type as well as length of experience. Any offered salary is also based on internal equity, internal salary ranges, market data, and the position’s wage range. The salary range listed does not include any applicable bonuses or long-term incentives, differential pay or other forms of compensation or benefits. Harpoon is a multistate employer and the salary offered will be market competitive. At Harpoon, it is not typical for an individual to be hired at or near the top of the range for their role and compensation decisions are dependent on the facts and circumstances of each case.